Gaurav Doshi
Research Subjects
Gaurav Doshi has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Hemant Devidas Une
Department of Pharmacology, Y. B. Chavan College of Pharmacy, Rouzabagh, Aurangabad, Maharashtra, India
7 shared publications Muqtada Shaikh
SVKM's Dr Bhanuben Nanavati College of Pharmacy, India
7 shared publications- Pratip Kashinath Chaskar
Department of Pharmacology and Pharmaceutical Chemistry, Vivekanand Education Society's College of Pharmacy, Mumbai, Maharashtra, India
6 shared publications Angel Godad
Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India
4 shared publications- Angel Godad
Department of Pharmacology, SVKM’S Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India
4 shared publications Pravin Kale
Department of Pharmacology, SVKM’S Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, 400 056, India
4 shared publications
Latest Publications
- 10 November 2026
- Published by Georg Thieme Verlag KG in Drug Research
Chelidonic Acid Monohydrate Attenuates Isoproterenol-Induced Myocardial Infarction via Modulation of Nuclear Factor Erythroid 2-Related Factor 2/Nuclear Factor Kappa B–Mediated Oxidative Stress and Inflammation
This study aimed to assess the cardioprotective activity of chelidonic acid monohydrate in an isoproterenol-induced myocardial infarction model in rats. Chelidonic acid monohydrate was administered orally at doses of 5, 10, and 20 mg/kg for 7 days, and its effects were evaluated using hemodynamic, electrocardiographic, morphometric, biochemical, and histopathological parameters. Chelidonic acid monohydrate demonstrated significant cardioprotective activity at doses of 10 and 20 mg/kg, as evidenced by improvements in hemodynamic and biochemical parameters, along with attenuation of structural changes such as cardiac hypertrophy and the normalization of electrocardiographic patterns. Treatment with chelidonic acid monohydrate also significantly reduced myocardial injury and fibrosis. Furthermore, chelidonic acid monohydrate modulated oxidative stress and inflammatory pathways as indicated by increased levels of antioxidant enzymes (superoxide dismutase and catalase) and decreased levels of pro-inflammatory mediators (nuclear factor kappa B, tumor necrosis factor-alpha, and interleukin-6). Molecular docking studies confirmed strong binding affinities of chelidonic acid monohydrate to key myocardial infarction–related targets, including nuclear factor erythroid 2–related factor 2, nuclear factor kappa B, tumor necrosis factor-alpha, and interleukin-6, with binding free energy values of−7.84,−7.59,−6.12, and−6.41 kcal/mol, respectively. Overall, these findings suggest that the cardioprotective effects of chelidonic acid monohydrate are mediated through modulation of the nuclear factor erythroid 2–related factor 2/nuclear factor kappa B pathway. This study provides compelling evidence supporting chelidonic acid monohydrate as a potential therapeutic agent for myocardial infarction, warranting further studies to assess its long-term efficacy.
- 10 November 2026
- Published by Georg Thieme Verlag KG in Drug Research
Chelidonic Acid Monohydrate Attenuates Isoproterenol-Induced Myocardial Infarction via Modulation of Nuclear Factor Erythroid 2-Related Factor 2/Nuclear Factor Kappa B–Mediated Oxidative Stress and Inflammation
This study aimed to assess the cardioprotective activity of chelidonic acid monohydrate in an isoproterenol-induced myocardial infarction model in rats. Chelidonic acid monohydrate was administered orally at doses of 5, 10, and 20 mg/kg for 7 days, and its effects were evaluated using hemodynamic, electrocardiographic, morphometric, biochemical, and histopathological parameters. Chelidonic acid monohydrate demonstrated significant cardioprotective activity at doses of 10 and 20 mg/kg, as evidenced by improvements in hemodynamic and biochemical parameters, along with attenuation of structural changes such as cardiac hypertrophy and the normalization of electrocardiographic patterns. Treatment with chelidonic acid monohydrate also significantly reduced myocardial injury and fibrosis. Furthermore, chelidonic acid monohydrate modulated oxidative stress and inflammatory pathways as indicated by increased levels of antioxidant enzymes (superoxide dismutase and catalase) and decreased levels of pro-inflammatory mediators (nuclear factor kappa B, tumor necrosis factor-alpha, and interleukin-6). Molecular docking studies confirmed strong binding affinities of chelidonic acid monohydrate to key myocardial infarction–related targets, including nuclear factor erythroid 2–related factor 2, nuclear factor kappa B, tumor necrosis factor-alpha, and interleukin-6, with binding free energy values of−7.84,−7.59,−6.12, and−6.41 kcal/mol, respectively. Overall, these findings suggest that the cardioprotective effects of chelidonic acid monohydrate are mediated through modulation of the nuclear factor erythroid 2–related factor 2/nuclear factor kappa B pathway. This study provides compelling evidence supporting chelidonic acid monohydrate as a potential therapeutic agent for myocardial infarction, warranting further studies to assess its long-term efficacy.
- 2 November 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (21) , 9401-9421
The gut–kidney–brain axis in chronic kidney disease: mechanisms and nutritional interventions for cognitive protection
Our review explores the intricate interplay between chronic kidney disease (CKD), nutritional status, and cognitive decline, emphasizing the emerging role played by the gut–kidney–brain axis in maintaining neurovascular and metabolic integrity.
- 2 November 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (21) , 9401-9421
The gut–kidney–brain axis in chronic kidney disease: mechanisms and nutritional interventions for cognitive protection
Our review explores the intricate interplay between chronic kidney disease (CKD), nutritional status, and cognitive decline, emphasizing the emerging role played by the gut–kidney–brain axis in maintaining neurovascular and metabolic integrity.
- 8 October 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-13
TYK2–Wnt5a Crosstalk in Psoriatic Arthritis: A Hypothesized Immunopharmacological Axis for Inflammation and Structural Remodelling
Introduction: Psoriatic Arthritis (PsA) is a chronic immune-mediated inflammatory disease marked by synovitis, enthesitis, bone erosion, and pathological new bone formation, via the Interleukin-23/T helper cell-17 (IL-23/Th17) axis. Tyrosine Kinase 2 (TYK2) mediates downstream signaling of IL-23, IL-12, and type I Interferons (IFN-I), whereas Wnt5a regulates non-canonical Wnt signaling in inflammation and skeletal remodelling. This review proposes and examines TYK2- Wnt5a crosstalk in PsA as a testable mechanistic hypothesis rather than an established pathway. Methods: A narrative literature search was conducted using PubMed, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov, combining terms ‘TYK2’, ‘Wnt5a’, ‘Psoriatic arthritis’, and ‘Wnt/β-catenin’. Relevant peer-reviewed articles, clinical studies, and webpages published up to 2026 were evaluated with no lower date limit. Evidence on TYK2 signaling, Wnt5a-mediated pathways, PsA immunopathogenesis, bone remodelling, and TYK2-targeted therapies was critically synthesized in narrative form. Results: TYK2 drives Th17/Th1-mediated inflammation via IL-17 and IL-22, while Wnt5a promotes osteoclastogenesis and aberrant bone remodelling. Emerging evidence suggests that the TYK2- driven cytokine network may influence Wnt5a expression, creating a pathogenic link between chronic inflammation and structural damage. This proposed axis currently rests on parallel, circumstantial evidence rather than direct experimental demonstration that TYK2-dependent signaling regulates Wnt5a expression in PsA tissue and is treated throughout as a hypothesis requiring direct validation. Discussion: Understanding the TYK2-Wnt5a interaction could explain the coexistence of erosive and proliferative bone changes in PsA and may reveal combination or pathway-directed therapeutic strategies. Conclusion: The TYK2-Wnt5a axis is a promising, hypothesis-generating target in PsA; further mechanistic and clinical studies are needed to validate it therapeutically.
- 8 October 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27, 1-13
TYK2–Wnt5a Crosstalk in Psoriatic Arthritis: A Hypothesized Immunopharmacological Axis for Inflammation and Structural Remodelling
Introduction: Psoriatic Arthritis (PsA) is a chronic immune-mediated inflammatory disease marked by synovitis, enthesitis, bone erosion, and pathological new bone formation, via the Interleukin-23/T helper cell-17 (IL-23/Th17) axis. Tyrosine Kinase 2 (TYK2) mediates downstream signaling of IL-23, IL-12, and type I Interferons (IFN-I), whereas Wnt5a regulates non-canonical Wnt signaling in inflammation and skeletal remodelling. This review proposes and examines TYK2- Wnt5a crosstalk in PsA as a testable mechanistic hypothesis rather than an established pathway. Methods: A narrative literature search was conducted using PubMed, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov, combining terms ‘TYK2’, ‘Wnt5a’, ‘Psoriatic arthritis’, and ‘Wnt/β-catenin’. Relevant peer-reviewed articles, clinical studies, and webpages published up to 2026 were evaluated with no lower date limit. Evidence on TYK2 signaling, Wnt5a-mediated pathways, PsA immunopathogenesis, bone remodelling, and TYK2-targeted therapies was critically synthesized in narrative form. Results: TYK2 drives Th17/Th1-mediated inflammation via IL-17 and IL-22, while Wnt5a promotes osteoclastogenesis and aberrant bone remodelling. Emerging evidence suggests that the TYK2- driven cytokine network may influence Wnt5a expression, creating a pathogenic link between chronic inflammation and structural damage. This proposed axis currently rests on parallel, circumstantial evidence rather than direct experimental demonstration that TYK2-dependent signaling regulates Wnt5a expression in PsA tissue and is treated throughout as a hypothesis requiring direct validation. Discussion: Understanding the TYK2-Wnt5a interaction could explain the coexistence of erosive and proliferative bone changes in PsA and may reveal combination or pathway-directed therapeutic strategies. Conclusion: The TYK2-Wnt5a axis is a promising, hypothesis-generating target in PsA; further mechanistic and clinical studies are needed to validate it therapeutically.
- Open Access
- 16 September 2026
- Published by Springer Nature in Reproductive Sciences
- p. 1
Correction to: Deciphering the Role of ZEB1 as a Central Regulator of Epithelial–Mesenchymal Transition and Hormonal Resistance in Endometriosis
- 16 September 2026
- Published by Springer Nature in Reproductive Sciences
- p. 1
Open AccessCorrection to: Deciphering the Role of ZEB1 as a Central Regulator of Epithelial–Mesenchymal Transition and Hormonal Resistance in Endometriosis
- 9 September 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (10) , 1954-1977
Deciphering the Role of ZEB1 as a Central Regulator of Epithelial–Mesenchymal Transition and Hormonal Resistance in Endometriosis
Endometriosis is a chronic inflammatory and sex steroid hormone-dependent gynaecologic disease, characterised by endometrial cell proliferation outside the uterine cavity, often accompanied by fibrosis, progesterone resistance, and high recurrence despite hormonal and surgical interventions. Epithelial-mesenchymal transition (EMT) is important for establishment of lesions and invasiveness, but the upstream transcriptional regulators that integrate hormonal, inflammatory and epigenetic signals are incompletely defined. This review emphasises ZEB1 as a molecular integrator at the systems level in endometriosis pathogenesis. We reviewed evidence for selective upregulation of ZEB1 in ectopic lesions, where it inhibits epithelial adhesion molecules, stabilises mesenchymal differentiation and activates the attachment-invasion angiogenesis cascade required for lesion persistence. In addition to EMT, we discuss bidirectional crosstalk between ZEB1 and endocrine signalling, illustrating how oestrogen-mediated induction and suppression of progesterone receptor pathways converge to establish progesterone resistance. The review includes miR-200 family members, long non-coding RNAs and circular RNAs that strengthen ZEB1 expression through multilayered feedback mechanisms that perpetuate chronic inflammatory and pro-fibrotic microenvironments. Critically, it tackles translational complexity by incorporating the heterogeneity of lesions uncovered through single-cell and spatial transcriptomics, and by assessing the experimental models necessary to determine causal relevance. Additionally, it addresses the paradox of targeting ZEB1 therapeutically, considering its physiological function in endometrial regeneration and implantation. Understanding the oestrogen-ZEB1-TGF-β axis is critical for developing mechanism-based precision interventions for endometriosis. Graphical abstract
- 9 September 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (10) , 1954-1977
Deciphering the Role of ZEB1 as a Central Regulator of Epithelial–Mesenchymal Transition and Hormonal Resistance in Endometriosis
Endometriosis is a chronic inflammatory and sex steroid hormone-dependent gynaecologic disease, characterised by endometrial cell proliferation outside the uterine cavity, often accompanied by fibrosis, progesterone resistance, and high recurrence despite hormonal and surgical interventions. Epithelial-mesenchymal transition (EMT) is important for establishment of lesions and invasiveness, but the upstream transcriptional regulators that integrate hormonal, inflammatory and epigenetic signals are incompletely defined. This review emphasises ZEB1 as a molecular integrator at the systems level in endometriosis pathogenesis. We reviewed evidence for selective upregulation of ZEB1 in ectopic lesions, where it inhibits epithelial adhesion molecules, stabilises mesenchymal differentiation and activates the attachment-invasion angiogenesis cascade required for lesion persistence. In addition to EMT, we discuss bidirectional crosstalk between ZEB1 and endocrine signalling, illustrating how oestrogen-mediated induction and suppression of progesterone receptor pathways converge to establish progesterone resistance. The review includes miR-200 family members, long non-coding RNAs and circular RNAs that strengthen ZEB1 expression through multilayered feedback mechanisms that perpetuate chronic inflammatory and pro-fibrotic microenvironments. Critically, it tackles translational complexity by incorporating the heterogeneity of lesions uncovered through single-cell and spatial transcriptomics, and by assessing the experimental models necessary to determine causal relevance. Additionally, it addresses the paradox of targeting ZEB1 therapeutically, considering its physiological function in endometrial regeneration and implantation. Understanding the oestrogen-ZEB1-TGF-β axis is critical for developing mechanism-based precision interventions for endometriosis. Graphical abstract
- Open Access
- 1 September 2026
- Published by Scientific Scholar in Indian Journal of Physiology and Pharmacology
- p. 1-12
Sulindac attenuates isoproterenol-induced myocardial injury: In vivo and molecular docking evidence
Objectives: Myocardial infarction (MI) arises when blood flow to a particular region of the heart is obstructed, leading to myocardial injury and characteristic electrocardiographic (ECG) abnormalities. Dysregulation of the Wnt/β-catenin signalling pathway has been implicated in post-MI cardiac remodelling. This study aimed to evaluate the cardioprotective potential of sulindac, a β-catenin inhibitor, in an isoproterenol (ISO)-induced rat model of MI. Materials and Methods: Myocardial infarction was induced in Wistar rats by subcutaneous administration of ISO. Sulindac was administered orally at doses of 2, 4, and 10 mg/kg. ECG changes, blood pressure, heart rate, oxidative stress markers, cardiac biomarkers, histopathological alterations, and β-catenin levels were evaluated. Molecular docking was performed to investigate the interaction of sulindac with tumour necrosis factor-alpha (7JRA), β-catenin (1A9U), and human interleukin-6 (1ALU) using a validated docking protocol. Results: Sulindac treatment significantly reduced heart rate, cardiac biomarkers, oxidative stress, and β-catenin levels while improving blood pressure and antioxidant enzyme activity in a dose-dependent manner. Histopathological examination demonstrated reduced inflammatory cell infiltration and myocardial fibrosis in sulindac-treated animals. Molecular docking revealed favourable interactions of sulindac with TNF-α, β-catenin, and human interleukin-6, supporting its potential multi-target activity. Conclusion: Sulindac attenuated ISO-induced myocardial injury and was associated with reduced β-catenin levels and favourable molecular docking interactions with inflammatory mediators and β-catenin. These findings suggest that sulindac may exert cardioprotective effects, potentially through modulation of the Wnt/β-catenin signalling pathway. However, further molecular studies are required to confirm the underlying mechanism and support its therapeutic potential in myocardial infarction.
- 1 September 2026
- Published by Scientific Scholar in Indian Journal of Physiology and Pharmacology
- p. 1-12
Open AccessSulindac attenuates isoproterenol-induced myocardial injury: In vivo and molecular docking evidence
Objectives: Myocardial infarction (MI) arises when blood flow to a particular region of the heart is obstructed, leading to myocardial injury and characteristic electrocardiographic (ECG) abnormalities. Dysregulation of the Wnt/β-catenin signalling pathway has been implicated in post-MI cardiac remodelling. This study aimed to evaluate the cardioprotective potential of sulindac, a β-catenin inhibitor, in an isoproterenol (ISO)-induced rat model of MI. Materials and Methods: Myocardial infarction was induced in Wistar rats by subcutaneous administration of ISO. Sulindac was administered orally at doses of 2, 4, and 10 mg/kg. ECG changes, blood pressure, heart rate, oxidative stress markers, cardiac biomarkers, histopathological alterations, and β-catenin levels were evaluated. Molecular docking was performed to investigate the interaction of sulindac with tumour necrosis factor-alpha (7JRA), β-catenin (1A9U), and human interleukin-6 (1ALU) using a validated docking protocol. Results: Sulindac treatment significantly reduced heart rate, cardiac biomarkers, oxidative stress, and β-catenin levels while improving blood pressure and antioxidant enzyme activity in a dose-dependent manner. Histopathological examination demonstrated reduced inflammatory cell infiltration and myocardial fibrosis in sulindac-treated animals. Molecular docking revealed favourable interactions of sulindac with TNF-α, β-catenin, and human interleukin-6, supporting its potential multi-target activity. Conclusion: Sulindac attenuated ISO-induced myocardial injury and was associated with reduced β-catenin levels and favourable molecular docking interactions with inflammatory mediators and β-catenin. These findings suggest that sulindac may exert cardioprotective effects, potentially through modulation of the Wnt/β-catenin signalling pathway. However, further molecular studies are required to confirm the underlying mechanism and support its therapeutic potential in myocardial infarction.
- 25 August 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-26
Morning hypertension: circadian mechanisms, cardiovascular consequences, and emerging therapeutic perspectives
1. Chronic high blood pressure (BP), commonly known as Hypertension, is a major global health concern. Hypertension is a significant risk factor for cardiovascular, cerebrovascular, and organ damag...
- 25 August 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-26
Morning hypertension: circadian mechanisms, cardiovascular consequences, and emerging therapeutic perspectives
1. Chronic high blood pressure (BP), commonly known as Hypertension, is a major global health concern. Hypertension is a significant risk factor for cardiovascular, cerebrovascular, and organ damag...
- 24 July 2026
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 96 (1) , e70293
Natural Products Targeting Oxidative Stress–Inflammation Crosstalk in Endometriosis
Problem: Endometriosis is a chronic, estrogen‐dependent inflammatory disorder marked by ectopic endometrial‐like tissue growth, resulting in pelvic pain, infertility, and significant declines in quality of life. Despite extensive research, current therapies remain largely symptomatic and are often associated with recurrence, hormonal adverse effects, and compromised fertility outcomes. Growing evidence indicates that oxidative stress, chronic inflammation, mitochondrial dysfunction, altered immune surveillance and metabolic dysregulation are central drivers of lesion establishment and progression. However, these interconnected mechanisms are often examined in isolation, limiting translational progress. Method of Study: We provide a comprehensive, integrative analysis of the molecular and cellular pathways underlying endometriosis, with particular emphasis on oxidative stress–inflammation crosstalk, signalling cascades supporting lesion survival, and emerging metabolic and mitochondrial targets. By critically synthesising recent experimental, preclinical, and clinical findings, this review highlights mechanistic overlaps that may explain therapeutic resistance and disease recurrence. Furthermore, it evaluates novel pharmacological and nutraceutical interventions targeting redox imbalance, inflammatory mediators, and intracellular signalling pathways, thereby expanding the conceptual framework beyond conventional hormonal suppression. Rising global endometriosis prevalence and its socioeconomic burden necessitate a shift from purely symptomatic management to mechanism‐driven therapeutic strategies. Results: This review addresses that gap by consolidating dispersed evidence into a unified mechanistic perspective, identifying promising translational targets, and proposing future research directions. The insights provided will help in creating safer, fertility‐preserving and more durable treatments. Thus, we categorise natural products by: (1) translational development stage (in vitro to clinical candidate); (2) regulatory pathway (dietary supplement, herbal medicine, or pharmaceutical); and (3) clinical context (e.g., pain control, recurrence prevention, or fertility preservation). Conclusion: This structured, clinically‐oriented framework distinguishes the present synthesis from mechanistic reviews and serves to guide both future research design and rational integration of natural products into endometriosis therapeutic strategies.
- 24 July 2026
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 96 (1) , e70293
Natural Products Targeting Oxidative Stress–Inflammation Crosstalk in Endometriosis
Problem: Endometriosis is a chronic, estrogen‐dependent inflammatory disorder marked by ectopic endometrial‐like tissue growth, resulting in pelvic pain, infertility, and significant declines in quality of life. Despite extensive research, current therapies remain largely symptomatic and are often associated with recurrence, hormonal adverse effects, and compromised fertility outcomes. Growing evidence indicates that oxidative stress, chronic inflammation, mitochondrial dysfunction, altered immune surveillance and metabolic dysregulation are central drivers of lesion establishment and progression. However, these interconnected mechanisms are often examined in isolation, limiting translational progress. Method of Study: We provide a comprehensive, integrative analysis of the molecular and cellular pathways underlying endometriosis, with particular emphasis on oxidative stress–inflammation crosstalk, signalling cascades supporting lesion survival, and emerging metabolic and mitochondrial targets. By critically synthesising recent experimental, preclinical, and clinical findings, this review highlights mechanistic overlaps that may explain therapeutic resistance and disease recurrence. Furthermore, it evaluates novel pharmacological and nutraceutical interventions targeting redox imbalance, inflammatory mediators, and intracellular signalling pathways, thereby expanding the conceptual framework beyond conventional hormonal suppression. Rising global endometriosis prevalence and its socioeconomic burden necessitate a shift from purely symptomatic management to mechanism‐driven therapeutic strategies. Results: This review addresses that gap by consolidating dispersed evidence into a unified mechanistic perspective, identifying promising translational targets, and proposing future research directions. The insights provided will help in creating safer, fertility‐preserving and more durable treatments. Thus, we categorise natural products by: (1) translational development stage (in vitro to clinical candidate); (2) regulatory pathway (dietary supplement, herbal medicine, or pharmaceutical); and (3) clinical context (e.g., pain control, recurrence prevention, or fertility preservation). Conclusion: This structured, clinically‐oriented framework distinguishes the present synthesis from mechanistic reviews and serves to guide both future research design and rational integration of natural products into endometriosis therapeutic strategies.